On March 26, 2026, MetaVia, Inc. (MTVA) announced financial results for the fourth quarter and full year 2025 and provided a business update. The company expects to initiate the Phase 1 Part 3 trial of DA-1726, a dual oxyntomodulin analog that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist, in April 2026. This will be a 16-week titration study to evaluate 48 mg (1-step) and 64 mg (2-step) DA-1726 in obese but otherwise healthy adults. We anticipate topline results from the study in the fourth quarter of 2026. The company recently completed a public offering that generated $9.3 million in gross proceeds, which will finance operations into the fourth quarter of 2026.
